Price Alert

Biohaven Ltd. (BHVN)

NYSE: BHVN · Real-Time Price · USD

13.82

0.08 (0.58%)

At close: Sep 25, 2025, 3:59 PM

13.75

-0.51%

After-hours: Sep 25, 2025, 05:16 PM EDT

0.58% (1D)

Bid	13.4
Market Cap	1.46B
Revenue (ttm)	3.84M
Net Income (ttm)	-766.97M
EPS (ttm)	-7.46
PE Ratio (ttm)	-1.85
Forward PE	-2.37
Analyst	Buy
Dividends	n/a

Ask	14.1
Volume	2,061,632
Avg. Volume (20D)	2,128,888
Open	13.55
Previous Close	13.74
Day's Range	13.40 - 13.82
52-Week Range	12.79 - 55.70
Beta	3.50
Ex-Dividend Date	n/a

About BHVN

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol BHVN

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for BHVN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Biohaven Ltd. is scheduled to release its earnings on Nov 11, 2025, after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 week ago

+8.97%

Biohaven shares are trading higher after Citigroup... Unlock content with Pro Subscription

1 month ago

+6.34%

Biohaven shares are trading higher after the company announced that the FDA review of Troriluzole has moved forward without an advisory committee.

News

1 week ago · businesswire.com

Deadline Soon: Biohaven Ltd. (BHVN) Investors Who Lost Money Urged To Contact The Law Offices of Frank R.

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming September 12, 2025 deadline to participate as a lead plaintiff in the securities fraud class action law...

2 weeks ago · businesswire.com

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biohaven

NEW YORK--(BUSINESS WIRE)---- $BHVN #BHVN--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Biohaven Ltd. (“Biohaven” or the “Company”) (NYSE: BH...

3 weeks ago · businesswire.com

Biohaven Ltd. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - BHVN

LOS ANGELES--(BUSINESS WIRE)--Biohaven Ltd. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - BHVN.

1 month ago · seekingalpha.com

Biohaven: Despite Troriluzole Program Delay, FDA Review On Track For Q4 2025

Biohaven's troriluzole shows 50%-70% slowing of SCA disease progression, with FDA review now on track for Q4 2025 after a brief delay. FDA is no longer requiring an advisory committee meeting to revie...

1 month ago · fool.com

Why Biohaven Stock Zoomed More Than 6% Higher Today

On a very good Friday for the stock market, Biohaven's (BHVN 6.33%) performance was exceptional. The clinical-stage biotech's share price inflated by over 6% that trading session thanks to regulatory ...